Cypress Capital Group’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $931K | Hold |
5,941
| – | – | 0.09% | 153 |
|
|
2026
Q1 | $907K | Sell |
5,941
-25
| -0.4% | -$3.83K | 0.1% | 132 |
|
|
2025
Q4 | $823K | Buy |
5,966
+210
| +4% | +$27.5K | 0.09% | 130 |
|
|
2025
Q3 | $738K | Sell |
5,756
-20
| -0.3% | -$2.44K | 0.09% | 139 |
|
|
2025
Q2 | $699K | Buy |
5,776
+2,638
| +84% | +$297K | 0.09% | 135 |
|
|
2025
Q1 | $350K | Sell |
3,138
-20
| -0.6% | -$2.13K | 0.05% | 167 |
|
|
2024
Q4 | $307K | Sell |
3,158
-300
| -9% | -$32K | 0.04% | 228 |
|
|
2024
Q3 | $398K | Buy |
3,458
+39
| +1% | +$4.42K | 0.04% | 242 |
|
|
2024
Q2 | $364K | Sell |
3,419
-380
| -10% | -$38.1K | 0.04% | 236 |
|
|
2024
Q1 | $367K | Sell |
3,799
-105
| -3% | -$10.8K | 0.04% | 237 |
|
|
2023
Q4 | $394K | Sell |
3,904
-231
| -6% | -$22.3K | 0.05% | 233 |
|
|
2023
Q3 | $421K | Sell |
4,135
-152
| -4% | -$15.4K | 0.06% | 230 |
|
|
2023
Q2 | $433K | Sell |
4,287
-71
| -2% | -$7.1K | 0.06% | 231 |
|
|
2023
Q1 | $401K | Sell |
4,358
-10
| -0.2% | -$873 | 0.06% | 223 |
|
|
2022
Q4 | $396K | Sell |
4,368
-13
| -0.3% | -$1.09K | 0.06% | 228 |
|
|
2022
Q3 | $333K | Sell |
4,381
-55
| -1% | -$4.56K | 0.06% | 220 |
|
|
2022
Q2 | $375K | Sell |
4,436
-30
| -0.7% | -$2.63K | 0.06% | 223 |
|
|
2022
Q1 | $392K | Sell |
4,466
-676
| -13% | -$58.5K | 0.05% | 236 |
|
|
2021
Q4 | $450K | Buy |
5,142
+66
| +1% | +$5.48K | 0.06% | 220 |
|
|
2021
Q3 | $415K | Buy |
5,076
+159
| +3% | +$14.3K | 0.06% | 224 |
|
|
2021
Q2 | $448K | Hold |
4,917
| – | – | 0.06% | 216 |
|
|
2021
Q1 | $420K | Sell |
4,917
-5
| -0.1% | -$449 | 0.06% | 223 |
|
|
2020
Q4 | $464K | Sell |
4,922
-377
| -7% | -$32.9K | 0.07% | 204 |
|
|
2020
Q3 | $461K | Buy |
5,299
+601
| +13% | +$52.1K | 0.08% | 185 |
|
|
2020
Q2 | $411K | Buy |
4,698
+310
| +7% | +$26.8K | 0.08% | 184 |
|
|
2020
Q1 | $362K | Buy |
4,388
+156
| +4% | +$13.9K | 0.08% | 149 |
|
|
2019
Q4 | $401K | Sell |
4,232
-10
| -0.2% | -$897 | 0.07% | 173 |
|
|
2019
Q3 | $369K | Buy |
4,242
+114
| +3% | +$10.2K | 0.07% | 182 |
|
|
2019
Q2 | $377K | Sell |
4,128
-32
| -0.8% | -$2.71K | 0.07% | 177 |
|
|
2019
Q1 | $358K | Buy |
4,160
+427
| +11% | +$34.3K | 0.07% | 186 |
|
|
2018
Q4 | $287K | Buy |
3,733
+346
| +10% | +$26.9K | 0.07% | 200 |
|
|
2018
Q3 | $261K | Buy |
+3,387
| New | +$250K | 0.05% | 217 |
|
Other funds holding NVS
Cypress Capital Group's NVS Position: Q2 2026 in Review
Cypress Capital Group held its Novartis (NVS) position steady in Q2 2026 at 5,941 shares worth $931K. The position accounts for 0.09% of the portfolio, ranked #153.
Cypress Capital Group first reported a position in NVS in Q3 2018 and has held it in 32 quarters since. 1,269 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Cypress Capital Group held 5,941 shares of Novartis worth $931K as of Q2 2026.
- Cypress Capital Group left its Novartis share count unchanged in Q2 2026.
- Novartis made up 0.09% of Cypress Capital Group's portfolio in Q2 2026, its #153 holding.
- Cypress Capital Group first reported a position in Novartis in Q3 2018 and has held it in 32 quarters since.
- 1,269 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Cypress Capital Group's 13F filing for Q2 2026, filed 5 Aug 2026.